Spica Healthcare — Unit of Grover Hospital, Bathinda
HomeHealth Guides & BlogsPrecision Oncology & Cancer GenomicsLiquid Biopsy & Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer (NSCLC): Actionable Resistance Mutations & Minimal Residual Disease (MRD)
Precision Oncology & Cancer Genomics

Liquid Biopsy & Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer (NSCLC): Actionable Resistance Mutations & Minimal Residual Disease (MRD)

9 min read
Sep 12, 2026
Spica Healthcare Clinical & Surgical Protocol Illustration #140

Clinical Summary & Key Takeaways

A precision oncology guide on liquid biopsy ctDNA next-generation sequencing in non-small cell lung cancer, evaluating EGFR/ALK drivers, Osimertinib resistance mechanisms (C797S, MET), and minimal residual disease tracking.

CRITICAL CLINICAL RED FLAG: In patients on targeted TKIs for metastatic EGFR/ALK NSCLC, asymptomatic molecular disease progression can precede radiographic RECIST enlargement by 2 to 6 months; serial ctDNA liquid biopsy enables early intervention before symptomatic clinical deterioration.

1. The Clinical Power of Plasma-Based Next-Generation Sequencing

While tissue biopsy remains the gold standard for initial histological diagnosis of Non-Small Cell Lung Cancer (NSCLC), up to 30% of patients have insufficient or inaccessible tissue for comprehensive biomarker testing. Liquid biopsy via cell-free circulating tumor DNA (ctDNA) overcomes spatial tumor heterogeneity and provides rapid, non-invasive genomic profiling with turnaround times under 7 to 10 days.

  • First-Line Driver Mapping: Detects classic EGFR (Exon 19 del, L858R), ALK/ROS1 fusions, RET fusions, MET Exon 14 skipping, BRAF V600E, and KRAS G12C mutations.

  • Resistance Mechanism Tracking: Identifies secondary resistance mutations following Osimertinib failure, including EGFR C797S, MET amplification, and small cell histological transformation.

  • Minimal Residual Disease (MRD): Post-surgical ctDNA clearance predicts curative resection vs. high risk of distant metastatic relapse in early-stage NSCLC.

2. Liquid Biopsy in Curative-Intent Adjuvant Care (ADAURA Era)

In resected Stage IB-IIIA EGFR-mutated NSCLC, patients who remain ctDNA-positive following surgical resection and adjuvant Osimertinib demonstrate imminent micrometastatic recurrence. Serial plasma monitoring enables personalized treatment intensification or switch therapies months before lesions appear on PET-CT scans.

"Liquid biopsy is not just a diagnostic tool; it is a real-time molecular window into tumor clonal evolution, allowing us to anticipate and neutralize drug resistance before cancer spreads." — Dr. Neha Gupta

3. Clinical Decision Algorithm: When to Order Liquid vs. Tissue Biopsy

According to ASCO and IASLC guidelines:

  1. Positive ctDNA result: Actionable and sufficient to immediately initiate targeted TKI therapy without requiring repeat invasive tissue biopsy.

  2. Negative ctDNA result: Requires tissue biopsy confirmation (reflex testing) due to potential false negatives in low-shedding or intracranial-only lesions.

4. Peer-Reviewed References & Clinical Guidelines

1. Rolfo C, Mack P, Scagliotti GV, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer (IASLC). Journal of Thoracic Oncology (JTO), 2021; 16(10): 1647-1662.

2. Tsuboi M, Herbst RS, John T, et al. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC (ADAURA Trial). New England Journal of Medicine (NEJM), 2023; 389: 137-147.

3. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Tyrosine Kinase Inhibitors: Guideline from CAP, IASLC, and AMP. Arch Pathol Lab Med, 2018; 142(3): 321-346.

Frequently Asked Patient Questions

Limb Salvage with modular titanium megaprosthesis removes the tumor completely while preserving the limb, allowing patients to walk, work, and maintain full social independence without the physical disability of an artificial limb.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Senior Consultant & Clinical Director — Medical Oncology

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Share this medical guide:
WhatsApp
Director-Led Clinical Breakthroughs

Signature Surgical Innovations & Techniques

Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

1 of 13
Comprehensive Bone Cancer Oncology & Limb Preservation
Click to Watch Video Demonstration
95%+ Limb Salvage & MAP Chemotherapy
Multidisciplinary Limb Salvage, MAP Chemotherapy & Modular Megaprosthetics

Comprehensive Bone Cancer Oncology & Limb Preservation

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.

Key Advantages Over Conventional Surgery:
Coordinated Surgical & Medical Oncology: Seamless dual leadership under Dr. Deepak Garg & Dr. Neha Gupta
95%+ Limb Preservation Rate: Wide oncological bone resection avoiding traumatic limb amputations
High-Grade Sarcoma Chemotherapy: Standardized MAP and VIDE protocols delivering high tumor necrosis rates (>90%)
Custom Modular Megaprostheses: Immediate joint restoration with biological tendon ingrowth collars
Why Families & Physicians Trust Spica

World-Class Clinical Precision, Built on Compassion

Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.

AIIMS & Tata Memorial Alumni25+ Yrs Combined Senior Leadership

15,000+ Complex Surgeries & 100% Director-Led Evaluations

Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.

15,000+Surgeries Completed
95%+Limb Salvage Rate
<0.3%Infection Benchmark
Pre-Op 3D Virtual Planning 100% Direct Director OPD Day-1 Walking Protocol
Sub-Millimeter Accuracy

3D Navigated Robotics & Day-1 Walking

Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.

ROSA Robotics & Stryker Nav
Malwa Punjab Exclusive

Limb-Salvage Over Amputation

South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.

Modular Megaprosthesis
0-Out-Of-Pocket Options

100% Cashless PM-JAY & TPAs

Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.

Ayushman + 30+ TPAs Empanelled
24/7 Tertiary Ready

Class-100 Laminar Flow OTs & ICU

Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.

Spica Healthcare Bathinda
Expert Surgical Directors

Meet the Doctors at Spica Healthcare

Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Dr. Neha Gupta - Clinical Director & Senior Medical Oncologist

Dr. Neha Gupta

Senior Consultant & Clinical Director — Medical Oncology

13+ Yrs Exp

MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

Medical Oncology & ChemotherapyImmunotherapy & Targeted OncologyPrecision Oncology & Cancer GenomicsPreventive Cancer ScreeningPalliative & Supportive OncologyHormonal TherapyComprehensive Cancer Treatments
Dr. Deepak Garg - Director & Senior Joint Replacement, Spine and Orthopaedic Oncologist

Dr. Deepak Garg

Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery

16+ Yrs Exp

MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)

Orthopaedic Oncology & Bone Tumors3D Robotic Joint ReplacementSports Injuries & ArthroscopyTrauma & Fracture ReconstructionGeneral Orthopaedics & Spine CareComprehensive Cancer Treatments
Community Health & Academic Outreach

Upcoming Health Camps & Academic Events

Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.

Curious what families & patients experience

Hear what our patients are saying

Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.

Health Knowledge & Clinical Guides

Doctor-Authored Health Guides

Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.